Introduction Low back pain is a common problem worldwide causing deterioration of health and quality of life. Low back pain is often associated with muscle spasm. We investigated the combined effect of muscle relaxants and pain killers for low back pain. Methods In this open-label, prospective, multicenter study, patients with acute low back pain received a single tablet of either the fixed dose combination of chlorzoxazone 500 mg and ibuprofen 400 mg (manufacturer: Dr. Reddy’s Laboratories, India) (C + I group) or ibuprofen 400 mg (I group) thrice daily for up to 7 days. Primary outcomes were improvement in pain by Visual Analogue Scale (VAS) and Summed Pain Intensity Difference (SPID) at 3 and 7 days post-treatment. Results A total of 406 patients were included in this study. When compared to baseline, the absolute mean change in VAS scores on Day 7 was 62.39 ± 18.78 and 57.34 ± 16.29 in the C + I and I groups, respectively ( P = 0.0001). In the C + I and I groups, the mean SPID at Days 3 and 7 were 51.27 ± 24.44 and 47.80 ± 22.91, and 300.82 ± 92.40 and 277.16 ± 81.83, respectively. No deaths or serious adverse events were reported. Common adverse events included gastritis, stomach pain, fever, cold, and headache. At the end of the study, excellent to good response was reported in 94.08% and 77.33% of patients in the C + I and I groups, respectively. Excellent to good tolerability was observed in 96.05% and 89.65% patients in the two groups, respectively. Conclusion Fixed dose combination of chlorzoxazone and ibuprofen demonstrated superior efficacy than ibuprofen monotherapy in acute low back pain. Both drugs were well-tolerated and should be considered as judicious therapeutic options in patients with acute low back pain. Trial Registration This trial is registered with Clinical Trial Registry of India—CTRI/2016/10/007348. Funding Dr. Reddy’s Laboratories Ltd.

No abstract

No abstract

Rheumatoid arthritis is the inflammatory disease affecting the joints and imposes significant burden among the individuals. Oxidative stress is one of the major mechanisms involved in the progression of arthritis. It is postulated that inflammation and secretion of various inflammatory cytokines also plays pivotal role in rheumatoid arthritis. Tridax procumbens (Asteraceae) is one of the potent herb and possess various biological actions. So, the present study was carried out to evaluate the protective role of Tridax procumbens in a murine model of complete Freund's adjuvant (CFA) provoked arthritis. The rats were made arthritic by injecting 0.1ml CFA into rat hind paw by intradermal route. Tridax procumbens methanolic extract (200 and 400 mg/kg, b.wt) were administered orally daily for 28 days after induction of arthritis. The anti arthritic effect was evaluated by, alterations in paw volume and body weight, changes in hematological parameters, increased lipid peroxidation and decreased antioxidants (SOD, CAT, GPx and GSH) due to arthritis. Treatment with Tridax procumbens significantly reduced the paw volume and increased the body weight in arthritic rats. Further, treatment with Tridax procumbens significantly increased the RBC and hemoglobin and decreased the WBC and ESR level as compared to the arthritic rats. The antioxidant levels were significantly increased in arthritic rats after treatment with extracts. Thus the anti-arthritic potential of Tridax procumbens might be mediated through antioxidant and anti-inflammatory effect of the extracts